Store
The Worldwide Market for Liquid Biopsy, 7th Edition
Publication Date: December 16, 2025
Tags: Cancer, Diagnostics, Genetic Diseases, Liquid Biopsy, Oncology and Cancer
Pages: 180
SKU: 25-048KA
Liquid biopsies have transformed cancer diagnostics by offering a minimally invasive method to analyze tumor-derived materials circulating in biological fluids. This approach provides critical insights for cancer detection, therapy selection, and disease monitoring, complementing or replacing traditional tissue biopsies and imaging techniques that often carry procedural risks and limitations.
Kalorama Information’s The Worldwide Market for Liquid Biopsy, 7th Edition explores the full spectrum of clinical applications driving adoption, including early detection and screening, alternative testing when tissue biopsy is impractical, therapy personalization and monitoring for resistance, disease surveillance for progression and recurrence, and prognostic assessment.
Comprehensive Market Analysis
The Worldwide Market for Liquid Biopsy, 7th Edition delivers a detailed forecast of global liquid biopsy revenues from 2025 to 2030, segmented by:
- Geographic Region: North America, Europe, Asia, and Rest of World, with regional market shares and growth trends.
- Technology Type: Circulating Tumor DNA (ctDNA)-based, Circulating Tumor Cell (CTC)-based, Extracellular Vesicle and Exosome-based, Multi-Analyte-based, and other analyte-driven approaches, including comparative tables of advantages and limitations.
- Cancer Type: Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, and Other Cancers, with revenue forecasts and share analysis for each indication.
- Application: Diagnosis and Screening, Therapy Guidance, Minimal Residual Disease (MRD), and Disease Prognosis, supported by market sizing and growth projections.
Industry Insights and Competitive Landscape
The report profiles selected liquid biopsy tests currently available and in development, including ctDNA-based assays, CTC-based platforms, and multi-analyte solutions. It examines clinical versus research use and regulatory trends. Detailed chapters cover technology comparisons, analyte-specific market dynamics, and application-level opportunities, supported by over a dozen tables and figures illustrating revenue forecasts, market shares, and growth drivers.
Scope and Methodology
This report covers the global market for liquid biopsy testing. The market data pertains to global and regional revenues at the level of testing companies. This differs from most KI reports, which provide estimates at the level of IVD products. While systems and kits are not excluded, they were not the primary focus of this report. Most companies offer these tests as services.
The base year for data is 2025, with forecasts provided through 2030. Compound annual growth rates (CAGRs) are included for each segment.
Information and data on the global liquid biopsy market were obtained from a wide range of primary and secondary sources. Interviews were conducted with manufacturers of IVD products, clinical laboratory technicians, and other industry experts. Secondary sources included statistical and informational reports and articles from government agencies, trade associations, and independent publishing firms. Annual reports, public filings, and websites of leading companies were also reviewed to identify evolving product and market trends, assess competitive factors, and support the overall industry analysis. Selected Kalorama Information and Strategic Directions International (SDi) publications were also consulted for additional background and context. SDi is Kalorama Information’s sister publishing brand with the Science and Medicine Group.
Chapter One: Executive Summary
About Kalorama Information
Scope and Methodology
Introduction
Liquid Biopsy Technologies
Industry Structure
Liquid Biopsy Market Revenues and Forecast
- Figure 1-1: Global Market for Liquid Biopsy, 2025-2030 ($ million)
- Figure 1-2: Global Liquid Biopsy Market, Share by Geographic Region, 2025 (%)
- Figure 1-3: Global Liquid Biopsy Market, by Geographic Region, 2025 vs. 2030 ($ million) [Asia Pacific, Europe, North America, Rest of World]
Chapter Two: Liquid Biopsy Technologies
Introduction
Major Liquid Biopsy Technologies
Chapter Three: Circulating Tumor DNA (ctDNA) Liquid Biopsy
Introduction
Advantages and Limitations of ctDNA in Liquid Biopsy
ctDNA-based Liquid Biopsy Tests
Adaptive Biotechnologies
Biocartis
Biodesix
CellMax Life
Circulogene
DiaCarta
Foundation Medicine (Roche)
Guardant Health
LungLife AI
Myriad Genetics
Natera
NeoGenomics
OncoDNA
Personal Genome Diagnostics (Labcorp)
QIAGEN
Resolution Biosciences (Exact Sciences)
Roche Diagnostics
Sysmex-Inostics
Tempus
ctDNA-based Liquid Biopsy Tests in Development
BillionToOne
Cyclomics
Exact Sciences
Freenome
GRAIL
Chapter Four: Circulating Tumor Cells (CTCs) Liquid Biopsy
Introduction
Challenges in the Development of CTC-based Liquid Biopsy Tests
CTC-based Liquid Biopsy Tests
Adaptive Biotechnologies
ANGLE
CellMax Life
Epic Sciences
GILUPI
LungLife AI
Menarini-Silicon Biosystems
QIAGEN
Selected CTC-based Liquid Biopsy Tests in Development
BioFluidica
Epic Sciences
QCDx
Chapter Five: Extracellular Vesicles and Other Liquid Biopsy
Introduction
Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
Biodesix
Exosome Diagnostics
Mercy BioAnalytics
Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
EValuate Diagnostics
Insight Molecular Diagnostics (formerly OncoCyte)
Nanostics
VolitionRx
Chapter Six: Multi-Analyte Liquid Biopsy Tests
Introduction
Liquid Biopsy Tests Based on Multiple Analytes
Biodesix
Foundation Medicine (Roche)
LungLife AI
NeoGenomics
OncoDNA
Multiple Analyte-based Liquid Biopsy Tests in Development
Exact Sciences
Freenome
GRAIL
LungLife AI
Chapter Seven: Liquid Biopsy Tests for Research Use Only
Introduction
Liquid Biopsy Tests for Research Use Only
Agena Bioscience
DiaCarta
Exosome Diagnostics
Guardant Health
QIAGEN
Chapter Eight: Liquid Biopsy Industry Analysis
Introduction
Tiers of Competition
Competitive Factors
Significant Market Trends
Personalized Medicine
Increasing Global Life Expectancy
New Liquid Biopsy Products
Increasing Accessibility of Genetic Testing
Regulatory Hurdles
Third-Party Payor Coverage
Demonstrated Clinical Utility
Incidence Rates of Specific Cancers
Competitors No Longer in the Liquid Biopsy Market
Chapter Nine: Liquid Biopsy Market
Market Overview
- Figure 9-1: Global Liquid Biopsy Market, by Geographic Region, 2025 vs. 2030 ($ million) [Asia Pacific, Europe, North America, Rest of World]
Regional Market Overview
- Figure 9-2: Global Liquid Biopsy Market, Share by Geographic Region, 2025 vs. 2030 (%)
Clinical vs. Research Use
Market Forecast
Chapter Ten: Market by Analyte
Overall
Analyte Analysis
- Figure 10-1: Global Liquid Biopsy Market, by Analyte, 2025 vs. 2030 ($ million) [Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Multiple Analytes]
- Figure 10-2: Global Liquid Biopsy Market, Share by Analyte, 2025 vs. 2030 (%) [Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Multiple Analytes]
Circulating Tumor DNA
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
Circulating Tumor Cells
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
Extracellular Vesicles and Other Analytes
Market Overview
Applications
Technologies
Specimens
Revenue Forecast
Multiple Analytes
Market Overview
Revenue Forecast
Chapter Eleven: Market by Application
Overview
Application Analysis
- Figure 11-1: Global Liquid Biopsy Market, by Application, 2025 vs. 2030 ($ million) [Diagnosis and Screening, Disease Prognosis, Minimal Residual Disease (MRD), Therapy Guidance]
- Figure 11-2: Global Liquid Biopsy Market, Share by Application, 2025 vs. 2030 (%) [Diagnosis and Screening, Disease Prognosis, Minimal Residual Disease (MRD), Therapy Guidance]
Therapy Guidance and Monitoring
Market Overview
Revenue Forecast
Minimal Residual Disease (MRD)
Market Overview
Revenue Forecast
Diagnosis/Screening
Market Overview
Revenue Forecast
Disease Prognosis
Market Overview
Revenue Forecast
Chapter Twelve: Market by Cancer Type
Overall
Cancer Type Analysis
- Figure 12-1: Global Liquid Biopsy Market, by Cancer Type, 2025 vs. 2030 ($ million) [Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pan-Cancer Testing, Prostate Cancer, Other Cancers]
- Figure 12-2: Global Liquid Biopsy Market, Share by Cancer Type, 2025 vs. 2030 (%) [Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pan-Cancer Testing, Prostate Cancer, Other Cancers]
Pan-Cancer Tests
Market Overview
Revenue Forecast
Lung Cancer
Market Overview
Revenue Forecast
Prostate Cancer
Market Overview
Revenue Forecast
Colorectal Cancer
Market Overview
Revenue Forecast
Breast Cancer
Market Overview
Revenue Forecast
Ovarian Cancer
Market Overview
Revenue Forecast
Other Cancers
Market Overview
Revenue Forecast
Chapter Thirteen: Company Profiles
Adaptive Biotechnologies
Agena Bioscience, Inc.
ANGLE plc
Aspira Women’s Health
Biocartis Group NV
Biodesix
CellMax Life
Circulogene
DiaCarta, Inc.
Epic Sciences
Exact Sciences
Freenome, Inc.
GILUPI GmbH
GRAIL
Guardant Health, Inc.
Hologic
LungLife AI (formerly Cynvenio Biosystems)
MDxHealth
Menarini-Silicon Biosystems, Spa
Natera, Inc.
NeoGenomics Laboratories, Inc.
OncoDNA S.A.
Personal Genome Diagnostics
QIAGEN N.V.
Cell-free DNA Technologies
CTC Technologies
Exosome and miRNA Technologies
Resolution Biosciences (Exact Sciences)
Roche Diagnostics
Sysmex-Inostics, Inc.
Tempus AI
Related products
In Vitro Diagnostic (IVD) Trends and Market Update: November 2023
November 7, 2023
As in vitro diagnostic (IVD) testing returns to its vital role in healthcare, it remains a cornerstone in medical practice, providing crucial insights for physicians, from diagnosis to precision medicine. While COVID-19 testing sees a decline, it continues to influence total revenues for 2023. In this ever-changing landscape, characterized by new products, shifts in global…
Price range: $3,750.00 through $5,625.00
The Worldwide Market for Clinical Laboratory Services, 9th Edition
June 25, 2024
Understanding the clinical laboratory market is crucial for effective business planning. The Worldwide Market for Clinical Laboratory Services, 9th Edition answers essential questions such as the size of the service market for clinical testing, the types of tests that are in demand, and the future trajectory of this market 2023-2028. It also identifies the companies…
Price range: $5,000.00 through $7,500.00
The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 11th Edition
April 23, 2024
Explore the latest trends and forecasts in the point-of-care (POC) diagnostic tests market with Kalorama Information’s The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 11th Edition. Discover the key growth areas and technological advancements shaping the future of POC diagnostics.
Lab-based analyzers in hospitals and reference labs are the cornerstone of revenues in the in…
Price range: $7,000.00 through $10,000.00
